Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi has paid $9m milestone to Rib-X Pharmaceuticals under a research collaboration relating to RX-04 program for the treatment of drug resistant Gram-negative and Gram-positive pathogens.
Subscribe to our email newsletter
Rib-X’s RX-04 program employs a proprietary approach for rational drug design resulting in entirely novel classes of compounds.
Recently presented data confirmed the new compounds directly impact ribosome function and exert their anti-bacterial activity by interfering with protein synthesis.
As per the terms of the agreement, Sanofi has already paid $10m as an upfront payment to Rib-X.
The tie up allows Rib-X to get further research, preclinical, regulatory and commercial milestones from Sanofi in future.
Excluding those assets which are licensed to Sanofi, Rib-X retains its rights to the discovery platform and its future programs.
Additionally, Rib-X also holds a co-promotion option in the US on one of the molecules coming from the collaboration.